Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about SANTHERA PHARMACEUTICALS HOLDING AG
11/24Santhera's Board Calls Extraordinary General Meeting To Vote On Future Fundraisings
MT
11/24Santhera Provides Corporate Update and Calls Extraordinary General Meeting to Seek Appr..
DJ
11/24Santhera Pharmaceuticals Holding AG announced that it has received CHF 15 million in fu..
CI
11/23Santhera's Mid-Stage Trial For Duchenne Muscular Dystrophy Drug Shows Sustained Efficac..
MT
11/23Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completi..
AQ
11/17Santhera JV to Seek US FDA's New Drug Approval For Duchenne Muscular Dystrophy Treatmen..
MT
11/17Santhera and ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone in Duchen..
DJ
11/17Santhera Pharmaceuticals and ReveraGen Biopharma Announces Successful FDA Pre-NDA Meeti..
CI
11/04Santhera Appoints Stephanie Brown as President North America and Member of the Executiv..
AQ
11/04Santhera Pharmaceuticals Holding AG Appoints Stephanie Brown as President North America..
CI
10/18SANTHERA PHARMACEUTICALS : H1 Loss Narrows As Operating Expenses Decline
MT
10/15Santhera Announces First Half-Year 2021 Financial Results and Updates on Corporate Prog..
DJ
10/13SANTHERA PHARMACEUTICALS : 2021 Santhera Interim Report
PU
10/01Santhera will Publish its Interim Report for the First Half of 2021 on October 15, 2021
DJ
09/27SANTHERA PHARMACEUTICALS : ReveraGen Get US FDA Orphan Grant to Study Vamorolone in Becker..
MT
09/27SANTHERA PHARMACEUTICALS : Issues Remaining Shares in $22 Million Private Placement
MT
09/27ReveraGen and Santhera Announce FDA Orphan Grant Funding for Clinical Trial with Vamoro..
DJ
09/27Santhera Completes Subsequent Capital Increase for Financing Arrangements
DJ
09/23SANTHERA PHARMACEUTICALS : Vamorolone Improves Outcomes For Duchenne Muscular Dystrophy Pa..
MT
09/23SANTHERA PHARMACEUTICALS : Issues 10 Million Shares in Private Placement
MT
09/23Santhera and ReveraGen to Present Phase 2a/2b Efficacy and New Safety Data with Vamorol..
DJ
09/23Santhera Completes Capital Increase for Financing Arrangements
DJ
09/20SANTHERA PHARMACEUTICALS : Raises $48 Million Funds
MT
09/20SANTHERA PHARMACEUTICALS : H1 Loss Shrinks On Financial Gain From Bond Conversions
MT
09/20Santhera Secures CHF 45 Million in Funding and Announces Preliminary First Half-Year 20..
DJ
09/20Santhera Pharmaceuticals Holding AG announced that it expects to receive CHF 15 million..
CI
06/24SANTHERA PHARMACEUTICALS' : Vamorolone Shows Positive Results In Duchenne Muscular Dystrop..
MT
06/24Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with Vamorolon..
DJ
06/24Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. to Present Findings from Pivotal..
CI
06/24Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with Vamorolon..
GL
06/23SANTHERA PHARMACEUTICALS : Shareholders Approve all Board Proposals at Today's Annual Gene..
AQ
06/23SANTHERA PHARMACEUTICALS' : Trial For Raxone Meets Primary Endpoint In Vision Loss Disease
MT
06/23Santhera Announces Phase 4 LEROS Trial with Raxone(R) Met Primary Endpoint in Patients ..
DJ
06/23Santhera Pharmaceuticals Holding AG Announces Phase 4 LEROS Trial with Raxone« Met Prim..
CI
06/23Santhera Announces Phase 4 LEROS Trial with Raxone« Met Primary Endpoint in Patients wi..
GL
06/22Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting
GL
06/01SANTHERA PHARMACEUTICALS : Meets Primary Endpoint For Vamorolone In Duchenne Muscular Dyst..
MT
06/01SANTHERA PHARMACEUTICALS : and ReveraGen Announce Positive and Statistically Highly Signif..
AQ
06/01Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline R..
CI
05/27SANTHERA PHARMACEUTICALS : Vice Chair to Step Down
MT
05/27Santhera Publishes Agenda for its Annual General Meeting
GL
05/20Santhera Completes Capital Increase for Financing Arrangements
DJ
05/07SANTHERA PHARMACEUTICALS : gibt den ersten Handelstag der neuen Wandelanleihe an der SIX S..
PU
05/07Santhera Announces First Trading Day of New Convertible Bonds on SIX Swiss Exchange
GL
05/04SANTHERA PHARMACEUTICALS : gibt den Vollzug des Umtauschangebots und die Ausgabe einer neu..
PU
05/04Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Co..
DJ
05/03SANTHERA PHARMACEUTICALS : Announces Settlement of Convertible Bond Exchange Offer on
AQ
05/03SANTHERA PHARMACEUTICALS : gibt den Vollzug des Umtauschangebots für die Wandelanleihe per..
PU
04/30Santhera Completes Capital Increases for Financing Arrangements
DJ
04/29Santhera Pharmaceuticals Holding Ag Reports Earnings Results for the Full Year Ended De..
CI
04/29Santhera Pharmaceuticals Holding AG Auditor Raises 'Going Concern' Doubt
CI
04/28SANTHERA PHARMACEUTICALS : ReveraGen Biopharma Report Positive Long-Term Data For Vamorolo..
MT
04/28SANTHERA PHARMACEUTICALS : Accepts $49 Million in Conversion Offer For Bonds Due 2022
MT
04/28Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne..
GL
04/28Santhera Pharmaceuticals and ReveraGen Biopharma Announce New 2.5-Year Treatment Data w..
CI
04/27Santhera Reports End Results on Convertible Bond Exchange Offer
GL
04/26SANTHERA PHARMACEUTICALS : to Announce 2020 Results on April 29, 2021
AQ
04/23Santhera to Announce 2020 Results on April 29, 2021
GL
04/20SANTHERA PHARMACEUTICALS : Accepts $43 Million in Conversion Offer For Bonds Due 2022, Ext..
MT
04/20Santhera Reports Interim Results on Convertible Bond Exchange Offer
DJ
04/06SANTHERA PHARMACEUTICALS : Initiates Offer For $64 Million Convertible Bonds Due 2022
MT
04/06Santhera Commences Convertible Bond Exchange Offer and Continues to Seek Votes on the B..
GL
03/30SANTHERA PHARMACEUTICALS : Issues 2.2 Million Treasury Shares for Financing Arrangements
MT
03/30Santhera Completes Capital Increase for Financing Arrangements
GL
03/25SANTHERA PHARMACEUTICALS : Initiates Exchange Offer for $64 Million Bonds Due 2022
MT
03/25Santhera Launches Exchange Offer for its CHF 60 Million Convertible Bonds
GL
03/18SANTHERA PHARMACEUTICALS : Shareholders Approve all Board Proposals at Today's Extraordina..
DJ
03/18Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Me..
GL
03/10SANTHERA PHARMACEUTICALS : Issues Treasury Shares
MT
03/10Santhera Completes Capital Increase for Financing Arrangements
GL
03/09SANTHERA PHARMACEUTICALS : Fails to Get Bondholders' Vote on $64 Million Bond Restructurin..
MT
03/09SANTHERA PHARMACEUTICALS : Announces Results of Bondholders' Meeting
DJ
03/09Santhera Announces Results of Bondholders' Meeting
GL
03/03SANTHERA PHARMACEUTICALS : Completes First Six-Month Period in Mid-Stage Trial For Duchenn..
MT
03/03Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with ..
CI
1  2  3  4  5  6  7Next